dc.contributor.author |
Rueda, Fabián |
dc.contributor.author |
Cano-Garrido, Olivia |
dc.contributor.author |
Mamat, Uwe |
dc.contributor.author |
Wilke, Kathleen |
dc.contributor.author |
Seras-Franzoso, Joaquin |
dc.contributor.author |
Garcia-Fruitos, Elena |
dc.contributor.author |
Villaverde Corrales, Antonio |
dc.date |
2014 |
dc.identifier |
https://ddd.uab.cat/record/132797 |
dc.identifier |
urn:10.1007/s00253-014-6008-9 |
dc.identifier |
urn:oai:ddd.uab.cat:132797 |
dc.identifier |
urn:recercauab:ARE-78972 |
dc.identifier |
urn:articleid:01757598v98p9229 |
dc.identifier |
urn:scopus_id:84920257228 |
dc.identifier |
urn:wos_id:000344344500007 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/f779e99d-df44-47e3-a026-d1b3e504330d |
dc.format |
application/pdf |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Ministerio de Economía y Competitividad RTA2012-00028-C02-02 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-132 |
dc.relation |
Applied microbiology and biotechnology ; Vol. 98 issue 22 (Nov. 2014), p. 9229-9238 |
dc.rights |
open access |
dc.rights |
Tots els drets reservats. |
dc.rights |
https://rightsstatements.org/vocab/InC/1.0/ |
dc.subject |
E. coli |
dc.subject |
Recombinant protein |
dc.subject |
Inclusion bodies |
dc.subject |
Endotoxin |
dc.subject |
LPS |
dc.subject |
LPS-free |
dc.title |
Production of functional inclusion bodies in endotoxin-free Escherichia coli |
dc.type |
Article |
dc.description.abstract |
Escherichia coli is the workhorse for gene cloning and production of soluble recombinant proteins in both biotechnological and biomedical industries. The bacterium is also a good producer of several classes of protein-based self-assembling materials such as inclusion bodies (IBs). Apart from being a relatively pure source of protein for in vitro refolding, IBs are under exploration as functional, protein-releasing materials in regenerative medicine and protein replacement therapies. Endotoxin removal is a critical step for downstream applications of therapeutic proteins. The same holds true for IBs as they are often highly contaminated with cell-wall components of the host cells. Here, we have investigated the production of IBs in a recently developed endotoxin-free E. coli strain. The characterization of IBs revealed this mutant as a very useful cell factory for the production of functional endotoxin-free IBs that are suitable for the use at biological interfaces without inducing endotoxic responses in human immune cells |